- Home
- BAND vs ATAI Comparison
BAND vs ATAI Comparison
Compare BAND & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAND | ATAI |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2017 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BAND | ATAI |
|---|---|---|
| Price | $49.57 | $7.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $24.50 | $15.88 |
| AVG Volume (30 Days) | 755.1K | ★ 14.0M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,113,000.00 | $4,089,000.00 |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $6.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.26 | ★ 1227.60 |
| 52 Week Low | $12.50 | $3.27 |
| 52 Week High | $79.08 | $7.45 |
Technical Indicators
Market Signals| Indicator | BAND | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 62.24 |
| Support Level | $48.15 | $3.32 |
| Resistance Level | $55.62 | N/A |
| Average True Range (ATR) | 4.15 | 0.08 |
| MACD | 0.44 | -0.05 |
| Stochastic Oscillator | 48.56 | 50.23 |
Price Performance
Historical ComparisonAbout BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of its revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.